Skip to content
value.today

Actuate Therapeutics, Inc.

🇺🇸 Fort Worth, Texas, USAPharmaceuticalsFounded 2015
Total raised
$72 M
7 rounds on record
Latest round
$3 M
Feb 2024
First round on record
Mar 2017
Today
Went public
See the company page

Actuate Therapeutics, Inc. is listed today as Actuate Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

7 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Actuate Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$5 MPrivate placement after listing$2 to $10 million

Actuate Therapeutics, Inc.: Private sale, Jun 2025

Investors in this round

8 investors had bought by the notice of Jul 7, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $9 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew G.L. Mazar · Executive Officer
  • Daniel Schmitt · Executive Officer, Director
  • Paul Lytle · Executive Officer
  • Aaron G.L. Fletcher · Director
  • Amy G.L. Ronneberg · Director
  • Daniel G.L. Zabrowski · Director
  • Jason G.L. Keyes · Director
  • Roger G.L. Sawhney · Director
  • Todd G.L. Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering amount includes the aggregate gross proceeds that may be received in the future upon the cash exercise in full of warrants.”

Signed by Paul Lytle, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 7, 2025. Read the notice at the SEC.

equity, optionsSEC
Feb 2024$3 MNo. 7$2 to $10 million

Actuate Therapeutics, Inc.: Raise no. 7, Feb 2024

Investors in this round

1 investor had bought by the notice of Mar 6, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Schmitt · Executive Officer, Director
  • Aaron Fletcher · Director
  • Dan Zabrowski · Director
  • Leslie Kreis, Jr. · Director
  • Todd Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Schmitt, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 6, 2024. Read the notice at the SEC.

debt, optionsSEC
Sep 2022$19 MNo. 6$10 to $50 million

Actuate Therapeutics, Inc.: Raise no. 6, Sep 2022

Investors in this round

95 investors had bought by the notice of Dec 15, 2022: 95 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$19 M of $50 M offered; $31 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Schmitt · Executive Officer, Director
  • Aaron Glenn Louis Fletcher · Director
  • Dan Wayne Zabrowski · Director
  • Leslie Wayne Kreis, Jr. · Director
  • Todd Wayne Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in all US states

Remarks in the notice

  • On fees: “Represents the estimated maximum amount of commissions that may be earned. The placement agent will also receive warrants to purchase up to 2% of the securities it sells at an exercise price equal to 120% of the price paid by investors.”

Signed by Daniel Schmitt, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 15, 2022. Read the notice at the SEC.

equitySEC
Nov 2020$14 MNo. 5$10 to $50 million

Actuate Therapeutics, Inc.: Raise no. 5, Nov 2020

Investors in this round

14 investors had bought by the notice of Dec 10, 2020: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $50 M offered; $36 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Schmitt · Executive Officer, Director
  • Aaron Glenn Louis Fletcher · Director
  • Alex Wayne Andrianopoulos · Director
  • Leslie Wayne Kreis, Jr. · Director
  • Pascal Wayne Krotee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Schmitt, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2020. Read the notice at the SEC.

equitySEC
Oct 2019$7 MNo. 4$2 to $10 million

Actuate Therapeutics, Inc.: Raise no. 4, Oct 2019

Investors in this round

17 investors had bought by the notice of Nov 14, 2019: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel M. Schmitt · Executive Officer, Director
  • Aaron Glenn Louis Fletcher · Director
  • Alex Wayne Andrianopoulos · Director
  • Leslie Wayne Kreis, Jr. · Director
  • Neil Wayne Bajpayee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel M. Schmitt, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 14, 2019. Read the notice at the SEC.

equity, optionsSEC
Apr 2019$22 MNo. 3$10 to $50 million

Actuate Therapeutics, Inc.: Raise no. 3, Apr 2019

Investors in this round

21 investors had bought by the notice of May 13, 2019: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $24 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel M Schmitt · Executive Officer, Director
  • Aaron Glenn Louis Fletcher · Director
  • Leslie Wayne Kreis Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel M Schmitt, President and ceo. Source: SEC Form D, newest notice filed May 13, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2018$4 MNo. 2$2 to $10 million

Actuate Therapeutics, Inc.: Raise no. 2, Aug 2018

Investors in this round

18 investors had bought by the notice of Sep 12, 2018: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel M Schmitt · Executive Officer, Director
  • Aaron Glenn Louis Fletcher · Director
  • Leslie Wayne Kreis Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel M Schmitt, President and ceo. Source: SEC Form D, newest notice filed Sep 12, 2018. Read the notice at the SEC.

debt, optionsSEC
Mar 2017$3 MNo. 1$2 to $10 million

Actuate Therapeutics, Inc.: Raise no. 1, Mar 2017

Investors in this round

2 investors had bought by the notice of Mar 20, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Actuate Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel M Schmitt · Executive Officer, Director
  • Aaron Glenn Louis Fletcher · Director
  • Leslie Wayne Kreis, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel M. Schmitt, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 20, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Actuate Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2025

That is all the official record says: Actuate Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Actuate Therapeutics, Inc. are on record.

Investors#

25 named in official filings. Open an investor to see everything it has backed.

Investors in Actuate Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Bios Actuate Co-Invest III, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Actuate Co-Invest II, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Actuate Co-Invest I, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Advisors GP, LLCFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Capital Management, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Bios Clinical Opportunity Fund, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Bios Equity COF, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Equity Partners III, LPPrivate equitynot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Bios Equity Partners II, LPPrivate equitynot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Bios Equity Partners, LPPrivate equitynot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund III, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund III NT, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund III QP, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund II, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund II NT, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund II QP, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund I, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BIOS Fund I QP, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
BP Directors, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Cavu Advisors, LLCFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Cavu Management, LPFund or asset managernot statednot statedHeld Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024)SEC Form 3
Kairos-Actuate SPV, L.P.Fund or asset managernot statednot statedHeld Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024)SEC Form 3
Kairos SPV Fund LLCFund or asset managernot statednot statedHeld Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024)SEC Form 3
Kairos Venture Opportunities I, L.P.Venture capitalnot statednot statedHeld Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024)SEC Form 3
Kairos Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 95 investors.

Largest shareholders today

Institutions holding Actuate Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Actuate Therapeutics, Inc.
NameRoleNamed in
Andrew G.L. MazarExecutive officerJul 2025
Daniel SchmittExecutive officerJul 2025
Paul LytleExecutive officerJul 2025
Daniel M. SchmittExecutive officerNov 2019
Daniel M SchmittExecutive officerMay 2019
Aaron G.L. FletcherDirectorJul 2025
Amy G.L. RonnebergDirectorJul 2025
Daniel G.L. ZabrowskiDirectorJul 2025
Daniel SchmittDirectorJul 2025
Jason G.L. KeyesDirectorJul 2025
Roger G.L. SawhneyDirectorJul 2025
Todd G.L. ThomsonDirectorJul 2025
Aaron FletcherDirectorMar 2024
Dan ZabrowskiDirectorMar 2024
Leslie Kreis, Jr.DirectorMar 2024
Todd ThomsonDirectorMar 2024
Aaron Glenn Louis FletcherDirectorDec 2022
Dan Wayne ZabrowskiDirectorDec 2022
Leslie Wayne Kreis, Jr.DirectorDec 2022
Todd Wayne ThomsonDirectorDec 2022
Alex Wayne AndrianopoulosDirectorDec 2020
Pascal Wayne KroteeDirectorDec 2020
Daniel M. SchmittDirectorNov 2019
Neil Wayne BajpayeeDirectorNov 2019
Daniel M SchmittDirectorMay 2019
Leslie Wayne Kreis Jr.DirectorMay 2019

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.